MedTrace Logo

Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis

NCT04910464 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-08-05

No results posted yet for this study

Summary

In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.

Conditions

Interventions

DRUG

Tranexamic acid

administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.

OTHER

0.9% saline

administer the same volume (100ml normal saline) and same duration (first three days).

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Omar Soliman, MD · Omar makram

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-05
Primary Completion
2027-01-10
Completion
2027-01-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910464 on ClinicalTrials.gov